Revakinagene Taroretcel Side Effects

Applies to revakinagene taroretcel: intravitreal implant.

General adverse events

The most common adverse reactions were conjunctival hemorrhage, delayed dark adaptation, foreign body sensation, eye pain, suture related complications, miosis, conjunctival hyperemia, eye pruritus, ocular discomfort, vitreous hemorrhage, blurred vision, headache, dry eye, eye irritation, cataract progression or formation, vitreous floaters, severe vision loss, eye discharge, anterior chamber cell, and iridocyclitis.^[Ref]

Nervous system

• Common (1% to 10%): Headache^[Ref]

Ocular

• Very common (10% or more): Conjunctival hemorrhage (up to 31%), delayed dark adaptation (up to 23.1%), miosis (up to 15.4%), eye pain (up to 15%), foreign body sensation in eyes (up to 15%), conjunctival hyperemia (up to 11%)
• Common (1% to 10%): Anterior chamber cell, blurred vision, cumulative cataract incidence, dry eye, eye discharge, eye irritation, eye pruritus, iridocyclitis, ocular discomfort, severe visual loss (more than 15 letters), vitreous hemorrhage, vitreous floaters^[Ref]

Severe visual loss included one case of visual loss due to cataract formation.^[Ref]

Other

• Very common (10% or more): Suture related complication (up to 15.4%)^[Ref]

Suture related complications included exposed suture, foreign body sensation, conjunctival wound dehiscence, painful sutures, suture irritation, suture granuloma, scleral wound opening, and itchy suture.^[Ref]

See also:

Further information

Revakinagene taroretcel side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer